Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App




New Hematology Analyzer Brings High-Standard Reticulocyte Analysis to a Compact Platform

By LabMedica International staff writers
Posted on 03 Mar 2014
A new, reliable, easy-to-use hematology analyzer with integrated PC eliminates manual methods to enhance laboratory productivity while maintaining standardization.

Horiba Medical division of Horiba UK (Northhampton, UK) now offers the new "Pentra XLR compact 5 part DIFF" hematology analyzer, incorporating full reticulocyte parameters to facilitate the investigation and diagnosis of hemopoiesis and anemia. More...
As the latest addition to the Pentra family, the XLR brings Horiba’s gold standard reticulocyte technology with STAT capabilities to a smaller platform. This makes it well suited for space-restricted laboratories or those with a smaller workload, without compromising on quality.

The new, reliable, easy-to-use analyzer with integrated PC eliminates manual methods to enhance laboratory productivity and ensure standardization of reticulocyte count. The Pentra XLR’s large capacity autoloader and ability to process 80 samples per hour, combined with auto rerun, Customized Dilution Ratio (CDR) and automatic validation, all enable a hands-off approach. Users can thus dedicate valuable time to results analysis and more specialised needs.

Providing a high degree of flexibility, the new Pentra XLR has a microsampling system requiring only 53 µl of blood for FBC and 35 µl for full reticulocyte analysis, making it well suited for pediatric or other small samples. The reticulocyte channel utilizes Thiazole Orange technology, providing a full maturity profile in addition to a highly accurate reticulocyte count. It is also compatible with ABX Pentra ML data management, facilitating simple integration into existing systems.
The new Pentra XLR is built on the same proven reticulocyte technology as Horiba’s higher throughput Pentra analyzers, ensuring quality and full compatibility of results and reagents. With three quality control levels for all parameters, this robust and reliable platform also provides complete data traceability on-board and integrated validation, thus enhancing peace of mind also for the user.

“The Pentra XLR enhances laboratory productivity, flexibility and quality, adding value to any hematology laboratory,” said Cleve Wright, Horiba UK; “By incorporating full reticulocyte analytical capabilities, the Pentra XLR delivers high quality detailed analysis for highly accurate patient diagnosis on a compact platform.”

Related Links:

Horiba Medical



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.